Epidemiologia nowotworów neuroendokrynnych układu pokarmowego w Krakowie i powiecie krakowskim w latach 2007-2011.

Trofimiuk–Müldner, Małgorzata; Lewkowicz, Ewelina; Wysocka, K; Pach, Dorota; Kiełtyka, Agnieszka; Stefańska, Agnieszka; Sowa‐Staszczak, Anna; Tomaszewska, Romana; Hubalewska‐Dydejczyk, Alicja

doi:10.5603/ep.2017.0006

Cited by 8 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pancreas (30.7%) was the most frequent primary site of GEP‐NEN, similarly to reports by Garcia‐Carbonera et al in the Spanish registry (33.7%) and Wang et al from South China (34.8%) [8, 9]. Notably, most registries from Europe, Chile and Argentina find the small intestine as the most common primary site [12, 16–18]. However, in a recently published population‐based study from Iceland of 364 patients, the appendix (32%) was the most common primary origin at the time of diagnosis [19].…”

Section: Discussionsupporting

confidence: 69%

See 1 more Smart Citation

Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia

et al. 2019

View full text Add to dashboard Cite

Background Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare, heterogeneous group which tend to rise in incidence. Epidemiological profile and outcomes of GEP-NEN may vary among countries. The aim of study was to provide baseline clinical and histopathological features of patients with GEP-NEN from tertiary referral hospitals in Latvia. Methods A retrospective study of patients with histologically confirmed diagnosis of GEP-NEN treated between 2006 and 2018. Joinpoint regression modeling was used to estimate annual percentage change (APC) for incidence trends. Overall survival (OS) rate was obtained by Kaplan-Meier method. Results In total, 205 patients were included. The median age at diagnosis was 61.0 (IQR 52.0-70.5) years, 69.3% were females. The age-adjusted incidence per 100 000 inhabitants increased from 0.03 in 2006 to 0.67 in 2018 with APC of 24.1%, p \ 0.005. The most common primary tumor site was pancreas (30.7%), followed by stomach (24.9%) and small intestine (20.5%). Non-functional tumors are present in 83.4%, while carcinoid syndrome in 7.8%. Stage IV metastatic disease was present in 27.8% tumors. The majority of patients (82%) received an operation with radical or palliative intent. The 1-and 3-year OS rate were 88.0% (95% CI 83.3-92.7) and 77.1% (95% CI 70.4-83.8), respectively. Increasing tumor grade, stage and the presence of distant metastases were associated with significantly worse OS. Conclusion Our study highlights increasing incidence of GEP-NEN in Latvia. The most common primary site was pancreas and surgery considered as main modality of treatment. Registry and long-term data collection are necessary to develop GEP-NEN management concept in Latvia.This paper was presented as an oral presentation at the IAES meeting/ 48 th World Congress of Surgery August 11-15, 2019, in Krako ´w, Poland.

show abstract

Section: Discussionsupporting

confidence: 69%

“…Ito et al observed that the incidence rate of gastrointestinal NEN (excluding pancreas) in Japan in 2005 was 2.1 per 100,000 [11]. In Krakow, the incidence rate of GEP‐NEN ranged from 1.5 to 2.7 per 100,000 inhabitants per year [12]. Epidemiological data from Germany and Norway also showed an increase [13–15].…”

Section: Discussionmentioning

confidence: 99%

Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of neoplasms originating from cells of the diffuse endocrine system (DES), located in the gastrointestinal tract and the pancreas [ 14 ]. Neuroendocrine cells exhibit mixed morphological and physiological characteristics of both nervous and endocrine systems [ 15 , 16 ].…”

Section: Gastroenteropancreatic Neuroendocrine Tumorsmentioning

confidence: 99%

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms

et al. 2022

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare neoplasms, which, due to their heterogeneous nature, non-specific symptoms, and lack of specific tumor markers pose many diagnostic and clinical challenges. In recent years, the effectiveness of GEP-NEN diagnosis has increased, which is probably associated with the greater availability of diagnostic tests and the cooperation of many experienced specialists in various scientific disciplines. In addition to the possible genetic etiology, the cause of GEP-NET development is not fully understood. Inflammation and obesity are known risks that contribute to the development of many diseases. Chronic inflammation accompanying obesity affects the hormonal balance and cell proliferation and causes the impairment of the immune system function, leading to neoplastic transformation. This review explores the role of inflammation and obesity in GEP-NETs. The exact mechanisms inducing tumor growth are unknown; however, the profile of inflammatory factors released in the GEP-NET tumor microenvironment is responsible for the progression or inhibition of tumor growth. Both the excess of adipose tissue and the impaired function of the immune system affect not only the initiation of cancer but also reduce the comfort and lifetime of patients.

show abstract

Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience

Kunikowska

Zemczak

Kołodziej³

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Introduction One of the concepts of theranostics in nuclear medicine is peptide receptor radionuclide therapy (PRRT), whereby labeled somatostatin analogs are used for imaging and treating inoperable or disseminated neuroendocrine tumors (NET). Aim The aim of the study was to determine the therapeutic efficacy and toxicity of tandem 90 Y / 177 Lu-DOTATATE in patients with disseminated NET in a multicenter trial. Materials and methods 103 patients with NET G1/G2 treated with 90 Y/ 177 Lu-DOTATATE (1:1) with amino-acid infusion for nephroprotection were included in the study. Results Overall survival from the disease diagnosis (OS-D) was 127.4 months and from the time of PRRT (OS-T) was 89.5 months. Progression-free survival (PFS) was 29.9 months. An analysis based on the proliferation index revealed a statistically significant impact on PFS and OS-T (PFS G1 vs G2, 59.3 vs 24.3 months; OS-T G1 vs G2, not reached vs 79.9 months). The effect of the primary disease site was also analyzed. For pancreatic vs small bowel vs large bowel, the PFS was 30.8 vs 30.3 vs 40.6 months, the OS-T was 94 vs 61.9 vs 131.2 months and OS-D was 130.4 vs 89.2 vs not reached months, respectively. The 2-year risk of progression was 42%. The probability of 2-year and 5-year overall survival was 89% and 62%, respectively. PRRT was well tolerated by all patients. One patient (1%) developed myelodysplastic syndrome. No other grade 3 and 4 hematological or renal toxicity was observed. Conclusions This multicenter trial showed that tandem 90 Y/ 177 Lu-DOTATATE is highly effective and safe therapy for patients with disseminated NET.

show abstract

Epidemiologia nowotworów neuroendokrynnych układu pokarmowego w Krakowie i powiecie krakowskim w latach 2007-2011.

Cited by 8 publications

References 18 publications

Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia

Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia

Inflammation Related to Obesity in the Etiopathogenesis of Gastroenteropancreatic Neuroendocrine Neoplasms

Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience

Contact Info

Product

Resources

About